Seeking Alpha

Celgene's (CELG +1.9%) apremilast treatment for psoriatic arthritis meets primary efficacy goals...

Celgene's (CELG +1.9%) apremilast treatment for psoriatic arthritis meets primary efficacy goals in a Phase 3 study, and the biotech will now seek FDA and EU regulatory approval for the drug in 2013. Apremilast also achieved its primary goal in a separate study of patients with Behcet's disease, a rare inflammatory condition. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector